NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

NCT01370213 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Preparative Regimen
BIOLOGICAL: NK Cells
DRUG: Interleukin-2
BIOLOGICAL: CD34 Graft/Anti-thymocyte globulin
BIOLOGICAL: Donor TCR α/β-depleted Graft/ATG

Sponsor

Masonic Cancer Center, University of Minnesota